Immunotherapy is a promising approach in
the treatment of metastatic melanoma, an aggressive and deadly form of skin cancer; but for most patients, immunotherapy drugs so far have failed to live up to their promise and provide little or no benefit.
Dr. Wolchok is the Lloyd J. Old / Virginia and Daniel K. Ludwig Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK); chief of the Melanoma and Immunotherapeutics Service at MSK; and an attending physician at MSK with expertise in
the treatment of metastatic melanoma.
Recently, it approved the first intralesional therapy, talimogene laherparepvec (T - VEC), for
the treatment of metastatic melanoma lesions in the skin and lymph nodes.